Dr Jordan Lane, CSO of Ignota Labs, appointed Industry and Enterprise Fellow of Clare Hall Cambridge
Dr Jordan Lane, Chief Scientific Officer at Ignota Labs, has been appointed Industry and Enterprise Fellow of Clare Hall, Cambridge, for his extensive experience in the AI drug discovery space.
Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer
Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the appointment of Dr.
Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth
Optibrium, a leading developer of software and AI solutions for molecular design, today (8 July 2025) announced it has secured a strategic financing package with Shawbrook, a specialist UK bank that provides finance to established UK businesses on high growth trajectories.
SolasCure publishes Dose Escalation Study on painless application of Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the publication of a peer-reviewed study in the International Wound Journal1.
Cognidox launches integrated Learning Management System to strengthen compliance and training for medical device and life science companies
Cognidox announced the launch of its new Learning Management System (LMS) — a powerful tool designed to help startups and scaling organisations meet training compliance requirements with greater efficiency, transparency, and control.
Bio-Rad expands Droplet Digital PCR offering through strategic acquisition and platform rollout
HERCULES, Calif. — July 7, 2025 — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announces the launch of four new Droplet Digital™ PCR (ddPCR™) platforms.
A £14.5 Billion Opening: How UK life sciences firms can lead China’s healthcare transformation
On 2 July 2025, China’s Ministry of Finance, National Health Commission, and National Disease Control Administration jointly announced a RMB 20.92 billion (£14.5 billion) Major Public Health Service Subsidy Fund for 2025. This signals a bold continuation of healthcare system modernisation, including a 5.3% increase in per capita public health funding to RMB 99.
A Chinese perspective on England’s “Fit for the Future” NHS plan
In July 2025, England launched its ambitious “Fit for the Future” strategy—a 10-year vision to transform the National Health Service (NHS). By shifting care closer to communities, accelerating digital transformation, and prioritising prevention, the plan addresses the urgent challenges of an ageing population, chronic disease, and hospital pressures. These priorities are not unique to the UK;…
Groundbreaking science celebrated at prestigious technologies competition
Four winners share £100,000 prize pot to take the next steps to commercialising their technology. The winning scientists have developed exciting solutions to some of the biggest challenges we face today, in areas including antimicrobial resistance.
Milner Therapeutics Symposium showcases innovation in translational science
Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.
Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery
Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artificial intelligence. This first-of-its kind collaboration will apply Healx’s cutting-edge AI platform to identify…
Optibrium partners with TalTech on EU-Funded PhD Programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism
Founding fundraiser says Addenbrooke’s would not be what it is today without financial support of hospital charity
This month, Addenbrooke's Charitable Trust celebrates its 30th birthday. As the official charity for Addenbrooke’s, it funds high-tech equipment, specialist staff, extra comforts and vital research above and beyond what the NHS is able to provide. Here, one of the founding fundraisers, retired Professor of Radiology Adrian Dixon, talks about his early days of fundraising for the first whole body…
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues. Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who had been treated with a range of chemotherapies.
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
Study identifies new metrics to enhance scRNA-seq based virtual cell modellingFoundational paper to drive development of improved virtual cell models for rejuvenation target discoveryCambr
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today (01 July 2025) announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.
A scientist's view: Why marketing matters for science
A scientist and our Advisory Board Member Farah Aladin-Foster, shares why marketing is crucial for extending the reach of your research beyond academic journals and making a bigger impact in the science and tech community.
Radiotherapy and surgical ablation technologies for cancer treatment
Radiotherapy, or radiation ablation, has evolved significantly since its inception. Ongoing technological advancements have the potential to position radiotherapy as a first-line “surgical” treatment for solid tumours by enhancing its precision and efficacy. Further advancements in real-time imaging, adaptive dosing and advanced delivery techniques could give radiotherapy the potential to…
Achieve ISO Certification with expert guidance
Looking to implement or integrate ISO Standards in your business?
Guardtech Group set for Suffolk Business Awards showcase to kick off trio of events
The Haverhill-based contamination control specialists are up for the Large Business of the Year prize next month before setting their sights on two more awards later in the year.
25 years since the completion of the human genome project and the future of genomics
As it marks 25 years since the Human Genome Project, the Sanger Institute looks to a future where genomics drives better health and prevents disease.
Cambridge Cognition investment, Monument Therapeutics, achieves positive Phase I results for novel schizophrenia treatment
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved positive topline results from its Phase I clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia …
Zyme Communications celebrates 15 years of providing specialist support for the life science sector
Zyme Communications Ltd. (Zyme), the life science specialist PR and marketing agency, today (26 June 2025) celebrates its 15-year anniversary, and introduces refreshed branding to reflect this milestone and the Company’s continued development.